These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 16708557)
41. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Kremer JM; Weinblatt ME; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Jackson CG; Atkins KM; Feng A; Burge DJ Arthritis Rheum; 2003 Jun; 48(6):1493-9. PubMed ID: 12794815 [TBL] [Abstract][Full Text] [Related]
42. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Aggarwal P; Naik S; Mishra KP; Aggarwal A; Misra R Indian J Med Res; 2006 Nov; 124(5):521-6. PubMed ID: 17213520 [TBL] [Abstract][Full Text] [Related]
43. Cytokine (IL-6) and chemokine (IL-8) gene polymorphisms among rheumatoid arthritis patients in Taiwan. Lo SF; Huang CM; Lin HC; Chen WC; Tsai CH; Tsai FJ Clin Exp Rheumatol; 2008; 26(4):632-7. PubMed ID: 18799095 [TBL] [Abstract][Full Text] [Related]
44. Reduced folate carrier 1 gene expression levels are correlated with methotrexate efficacy in Japanese patients with rheumatoid arthritis. Tazoe Y; Hayashi H; Tsuboi S; Shioura T; Matsuyama T; Yamada H; Hirai K; Tsuji D; Inoue K; Sugiyama T; Itoh K Drug Metab Pharmacokinet; 2015 Jun; 30(3):227-30. PubMed ID: 26003891 [TBL] [Abstract][Full Text] [Related]
45. Rheumatoid arthritis: Methotrexate and bridging glucocorticoids in early RA. Onuora S Nat Rev Rheumatol; 2014 Dec; 10(12):698. PubMed ID: 25385411 [No Abstract] [Full Text] [Related]
46. [The short-term efficacy and safety of methotrexate plus low dose prednisone in patients with rheumatoid arthritis]. Liu SY; Yang L; Zhang L; Zhang X; He YJ Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1018-22. PubMed ID: 24503398 [TBL] [Abstract][Full Text] [Related]
47. The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. Ruiz-Padilla AJ; Gamez-Nava JI; Saldaña-Cruz AM; Murillo-Vazquez JD; Vazquez-Villegas ML; Zavaleta-Muñiz SA; Martín-Márquez BT; Ponce-Guarneros JM; Rodriguez Jimenez NA; Flores-Chavez A; Sandoval-Garcia F; Vasquez-Jimenez JC; Cardona-Muñoz EG; Totsuka-Sutto SE; Gonzalez-Lopez L Biomed Res Int; 2016; 2016():4193538. PubMed ID: 27738630 [No Abstract] [Full Text] [Related]
48. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Seitz M; Wirthmüller U; Möller B; Villiger PM Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636 [TBL] [Abstract][Full Text] [Related]
49. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Pawlik A; Wrzesniewska J; Fiedorowicz-Fabrycy I; Gawronska-Szklarz B Int J Clin Pharmacol Ther; 2004 Sep; 42(9):496-503. PubMed ID: 15487808 [TBL] [Abstract][Full Text] [Related]
50. Are glucocorticoids harmful to bone in early rheumatoid arthritis? Lems WF Ann N Y Acad Sci; 2014 May; 1318():50-4. PubMed ID: 24739059 [TBL] [Abstract][Full Text] [Related]
51. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis. Radstake TR; Fransen J; Toonen EJ; Coenen MJ; Eijsbouts AE; Donn R; van den Hoogen FH; van Riel PL Ann Rheum Dis; 2007 Nov; 66(11):1525-30. PubMed ID: 17456524 [TBL] [Abstract][Full Text] [Related]
52. Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis. Schotte H; Schlüter B; Schmidt H; Gaubitz M; Drynda S; Kekow J; Willeke P PLoS One; 2015; 10(6):e0130907. PubMed ID: 26107717 [TBL] [Abstract][Full Text] [Related]
53. Interleukin 6 gene polymorphism is associated with protein serum level and disease activity in Polish patients with rheumatoid arthritis. Wielińska J; Dratwa M; Świerkot J; Korman L; Iwaszko M; Wysoczańska B; Bogunia-Kubik K HLA; 2018 Dec; 92 Suppl 2():38-41. PubMed ID: 30054992 [TBL] [Abstract][Full Text] [Related]
54. Summaries for patients. Adding low-dose prednisone to methotrexate therapy for early rheumatoid arthritis. Ann Intern Med; 2012 Mar; 156(5):I18. PubMed ID: 22393145 [No Abstract] [Full Text] [Related]
55. Interleukin-1β, Interleukin1-Ra, Interleukin-10, and tumor necrosis factor-α polymorphisms in Tunisian patients with rheumatoid arthritis. Lagha A; Zidi S; Stayoussef M; Gazouani E; Kochkar R; Kochbati S; Almawi WY; Yacoubi-Loueslati B Pathol Biol (Paris); 2015 Sep; 63(4-5):179-84. PubMed ID: 26003199 [TBL] [Abstract][Full Text] [Related]
56. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Müller RB; von Kempis J; Haile SR; Schiff MH Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697 [TBL] [Abstract][Full Text] [Related]
57. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate. Ogrendik M South Med J; 2007 Feb; 100(2):135-9. PubMed ID: 17330681 [TBL] [Abstract][Full Text] [Related]
58. Survivin polymorphism is associated with disease activity in rheumatoid arthritis patients. Jenko B; Praprotnik S; Čučnik S; Rotar Ž; Tomšič M; Dolžan V Pharmacogenomics; 2016; 17(1):45-9. PubMed ID: 26651826 [TBL] [Abstract][Full Text] [Related]